Aakash Desai/LinkedIn
Mar 27, 2025, 08:26
Aakash Desai: Oncology dealmakers seek multi-indication therapies
Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on X:
“Oncology dealmaking dropped 50% in 2024 (~$90B), but cancer remains the top category.
Trends shaping the future:
- Shift from niche biomarker drugs to pan-cancer strategies
- Surge in ADCs, RLTs and bi/trispecifics
The race for next-gen precision plus scale is on!”
More posts featuring Aakash Desai .
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 16:03
Mar 30, 2025, 15:52
Mar 30, 2025, 15:48
Mar 30, 2025, 15:37
Mar 30, 2025, 15:24